Enanta began dosing in the LOTUS pediatric Phase 2b zelicapavir RSV trial, targets RESOLVE initiation in Q4, and expects Phase 1 EDP-978 topline data in Q4 2026.
Fiscal Q3 results and cash position
Enanta posted fiscal Q3 revenue of $14.4 million, down 21.6% year over year, on lower AbbVie MAVYRET/MAVIRET net sales.
Net loss widened to $19.5 million, or $0.67 per diluted share.
R&D expense fell to $22.1 million from $27.2 million, while interest expense more than doubled to $4.1 million.
Cash, cash equivalents and marketable securities totaled $211.5 million; Enanta expects funding into fiscal 2029 including retained royalties.
ENTA•
